ICTRP Search Portal

Main

Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.

Register:	EUCTR
Last refreshed on:	9 October 2012
Main ID:	EUCTR2009-009500-39-IT
Date of registration:	11/08/2009
Prospective Registration:	No
Primary sponsor:	ELI LILLY
Public title:
Scientific title:	A Randomized Trial Comparing either Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects with Type 2 Diabetes who were previously treated by basal insulin Glargine with either metformin or metformin and sulfonylurea - ND
Date of first enrolment:	09/07/2009
Target sample size:	760
Recruitment status:	Not Recruiting
URL:	https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-009500-39
Study type:	Interventional clinical trial of medicinal product
Study design:	Controlled: yes Randomised: yes Open: yes Single blind: no Double blind: no Parallel group: yes Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: yes Placebo: no Other: no
Phase:

Countries of recruitment
Estonia	Finland	France	Germany	Greece	Italy	Netherlands	Portugal
Spain	Sweden	United Kingdom

Contacts

Name:
Address:
Telephone:
Email:
Affiliation:

Name:
Address:
Telephone:
Email:
Affiliation:

Key inclusion & exclusion criteria

Inclusion criteria:
[1] Have T2DM (as defined by World Health Organization [WHO] classification; see Protocol Attachment GWDM.3). [2] Are at least 18 years of age. [3] Have been taking a basal insulin Glargine, at dose of ≥20 units/day, for at least 3 months prior to visit 1. [4] Have been taking basal insulin Glargine at dose of ≥20 units/day, in combination with 1 of the following OAM regimens, for at least 3 months prior to visit 1 [a] Metformin or immediate-release metformin or extended-release metformin alone at a maximum tolerated and stable dose with no less than 500 mg/day for at least 6 weeks prior to visit 1. Or [b] Metformin or immediate-release metformin or extended-release metformin at a maximum tolerated and stable dose with no less than 500 mg/day for at least 6 weeks prior to visit 1 and sulfonylurea at a stable dose for 6 weeks prior to visit 1. [5] Have an HbA1C >7.0% and ≤10.0%. [6] Have a body mass index (BMI) between ≥25 and ≤45 kg/m2. [7] Have a history of stable body weight (not varying by >10% for at least 3 months prior to visit 1. [8] Liver enzyme tests (alanine aminotransferase [ALT]; aspartate aminotransferase [AST]) are not greater than three times of the upper limit of the reference range (as defined by the Lilly-designated laboratory). [7] Pazienti con indici di funzione epatica (alanina aminotransferasi [ALT]; aspartato aminotransferasi [AST]) non superiori di 3 volte il limite superiore del range di normalita`. (Se i valori sono 1.5 volte superiori, ma comunque inferiori di 3 volte il limite superiore di normalita`, le transaminasi dovranno essere ripetute con un intervallo di 6 mesi). [8] Donne non in gravidanza oppure, se in eta` fertile, che adottino nel periodo dello studio un metodo sicuro di contraccezione come determinato dal medico.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion criteria:
[9] Are currently taking OAM that is not described above and not allowed with concurrent use of insulin per local product label. [10] Have taken more than 1 week within 1 month prior to the visit 1 any glucose-lowering medications not included in inclusion criteria [3] and [4] (for example those not approved for use with insulin, rosiglitazone, rimonabant, acarbose, miglitol, pramlintide, repaglinide, nateglinide or DPP-4 inhibitors, or pioglitazone) either alone or in combination formulations, or have used a drug for weight loss (for example, prescription drugs such as orlistat, sibutramine, phenylpropanolamine, rimonabant or similar over-the-counter medications) [11] Have taken any insulin other than Glargine within the 3 months prior to visit 1 for more than 1 week. [12] Are receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy (excluding topical, intraocular, and inhaled preparations) within 4 weeks prior to the visit 1 [13] Have had a clinically significant history of cardiac disease with functional status that is Class III or IV (New York Heart Association Class III or IV) (see Protocol Attachment 5) or considered by the investigator to be exclusionary. [14] Have had more than 1 episode of major hypoglycemia, as defined in the Abbreviations and Definitions section, within 6 months prior to visit 1 [15] Female subjects with a positive pregnancy test and/or intending to become pregnant or sexually active and not using birth control throughout the study to prevent pregnancy. [16] Women who are breastfeeding. [17] Have any of the following concomitant diseases: presence of clinically significant hematologic, oncologic, renal (or have creatinine clearance below 30 ml/min), cardiac, hepatic or gastrointestinal disease or any other serious disease considered by the investigator to be exclusionary. [18] Have fasting triglycerides levels > 500mg/dl ( >5.64mmol/l) [19] Have a history of renal transplantation or are currently receiving renal dialysis. [20] Have a history of confirmed pancreatitis [21] Have an active or untreated malignancy, or have been in remission from clinically significant malignancy (other than basal cell or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years. [22] Have contraindication or known hypersensitivity or allergy to Exenatide or to any of the product components (including prior withdrawal of Exenatide therapy after experiencing adverse events). [23] Have had a blood transfusion or severe blood loss within 3 months prior to visit 1 or have known hemoglobinopathy, hemolytic anemia, or sickle cell anemia, or any other condition known to interfere with the HbA1c methodology. [24] Have any other condition (including known drug or alcohol abuse or psychiatric disorder) that precludes the subject from following and completing the protocol, according to the investigators judgment. [25] Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an off-label use of an investigational drug or device (other than the study drug/device used in this study), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study. [26] Are investigator site personnel directly affiliated with this study and/or their immediate families.Immediate family is defined as a spouse, parent, child, or siblin

Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes

Health Condition(s) or Problem(s) studied

Type 2 Diabetes
MedDRA version: 9.1 Level: LLT Classification code 10012594

Intervention(s)

Trade Name: BYETTA
Pharmaceutical Form: Solution for injection
INN or Proposed INN: Exenatide
Concentration unit: µg microgram(s)
Concentration type: equal
Concentration number: 5-

Trade Name: BYETTA
Pharmaceutical Form: Solution for injection
INN or Proposed INN: Exenatide
Concentration unit: µg microgram(s)
Concentration type: equal
Concentration number: 10-

Trade Name: HUMALOG
Pharmaceutical Form: Solution for injection
INN or Proposed INN: Insulin lispro
Concentration unit: U/ml unit(s)/millilitre
Concentration type: equal
Concentration number: 100-

Primary Outcome(s)

Main Objective: The primary objective is to estimate the difference in change in HbA1c from randomization visit (Visit 2) to endpoint (30 weeks) between two regimens: BET (basal insulin Glargine and Exenatide) and BBT (basal insulin Glargine and bolus insulin insulin lispro TID) in subjects with type 2 diabetes and inadequate glycemic control, pretreated by basal insulin Glargine in combination with metformin alone or in combination of metformin and sulfonylurea. Non-inferiority will be concluded if the upper limit of the 95%-confidence interval (CI) for the treatment group difference (BET minus BBT) is <0.4% and <0.3%, respectively

Primary end point(s): The primary efficacy measure will be the change in HbA1c from baseline

Secondary Objective: to determine the clinical outcomes of the different treatment regimens in terms of: &#56256;&#56320; efficacy in terms of glycemic control, and other aspects e.g. body weight and insulin dose &#56256;&#56320; safety in terms of adverse events, hypoglycemia events and anti-Exenatide antibodies &#56256;&#56320; effects on cardiovascular parameters. &#56256;&#56320; Health outcomes &#56256;&#56320; Resource utilization

Secondary Outcome(s)

Secondary ID(s)

2009-009500-39-FR

H8O-EW-GWDM

Source(s) of Monetary Support

Secondary Sponsor(s)

Ethics review

Results

Results available:
Date Posted:
Date Completed:
URL:

Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.